March 26, 2018 / 11:10 AM / a month ago

BRIEF-Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Opdivo Four-Week Dosing Schedule For Advanced Melanoma And Previously Treated Renal Cell Carcinoma

March 26 (Reuters) - Bristol-Myers Squibb Co:

* BRISTOL-MYERS SQUIBB RECEIVES POSITIVE CHMP OPINION RECOMMENDING APPROVAL OF OPDIVO FOUR-WEEK DOSING SCHEDULE FOR ADVANCED MELANOMA AND PREVIOUSLY TREATED RENAL CELL CARCINOMA

* BRISTOL-MYERS SQUIBB CO - ‍CHMP RECOMMENDATION OF OPDIVO WILL NOW BE REVIEWED BY EUROPEAN COMMISSION​

* BRISTOL-MYERS - CHMP ALSO RECOMMENDED APPROVAL OF TWO-WEEK OPDIVO DOSING OPTION OF 240 MG TO REPLACE WEIGHT-BASED DOSING FOR APPROVED MONOTHERAPIES IN EU

* BRISTOL-MYERS SQUIBB CO - CHMP RECOMMENDATION WILL NOW BE REVIEWED BY EUROPEAN COMMISSION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below